Abstract
Abstract The incidence of hepatocellular carcinoma (HCC) has risen considerably in the US since 1980. The main causes include metabolic disorders (NAFLD, diabetes, obesity, metabolic syndrome), alcohol-related disease (ALD) and hepatitis C and B virus infections (HCV, HBV). Etiology-specific HCC incidence rates by detailed race-ethnicity are needed to improve HCC control and prevention efforts. All HCC cases diagnosed in Florida during 2005-2018 were linked to statewide hospital discharge data to determine etiology. Age-specific and age-adjusted rates were used to assess the intersection between etiology and detailed racial-ethnicities, including non-Hispanic White, non-Hispanic Black and Hispanic groups: Mexican, Cuban, Puerto Rican, Dominican, South, Central American. Of 19,956 HCC cases including 3,660 Hispanics, 87% matched with discharge data. For 2012-2018, HCV was the leading cause of HCC White, Black and Hispanic men (45.4%, 54.7% and 41.0% respectively) followed by NAFLD-related metabolic disorders and ALD. The leading cause of HCC among White and Black women was also HCV (38.3% and 50.2%) while for Hispanic women NAFLD-HCC (46.7%) was the most common form. Puerto Rican men had the highest HCV-HCC rates, 10.2 per 100 000. Metabolic-HCC rates were highest among populations above age 70 and among all Hispanics except Cubans. Mexican men had high rates of ALD-HCC. HCC etiology is associated with specific race/ethnicity. While HCV-related HCC rates are projected to decrease soon, HCC will continue to affect Hispanics disproportionately, based on higher rates of metabolic-HCC and ALD-HCC. Multifaceted approaches for HCC control and prevention are needed. Citation Format: Paulo S. Pinheiro. Liver cancer and differences across Hispanic groups: Importance of disaggregation in understanding cancer disparities [abstract]. In: Proceedings of the AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2021 Oct 6-8. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr IA-09.
